Figure 4. High AIMP mRNA expression subgroups are more responsive to anti-angiogenic therapies.
Kaplan-Meier survival analysis on retrospective clinical trials of recurrent GBM (REGOMA and BELOB trials). High expression sub-groups are stratified by median mRNA expressions of AIMP1/2/3. Log-rank p-value<0.05 is considered significant.
